Article Details
Retrieved on: 2022-02-15 02:09:11
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NRx's Zyesami can potentially help save patients who are seriously ill and have failed to respond to Gilead Sciences' Remdesivir.
Article found on: biobuzz.io
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here